Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 12/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23637705 | 0.88 | NR3C2 (0.55) | NR3C2MAPK14MAPK13 | |
| SCHEMBL16311110 | 0.84 | NR3C2 (0.52) | NR3C2MAPK14 | |
| SCHEMBL23637715 | 0.83 | MAPK14 (0.62) | NR3C2MAPK14MAPK13 | |
| SCHEMBL25918265 | 0.81 | MAPK14 (0.60) | NR3C2MAPK14MAPK13 | |
| SCHEMBL23015674 | 0.79 | NR3C2 (0.55) | NR3C2MAPK14 | |
| SCHEMBL28933414 | 0.77 | MAPK14 (0.59) | MAPK14MAPK13 | |
| SCHEMBL2642714 | 0.76 | LOXL2 (0.58) | NR3C2 | |
| SCHEMBL6951830 | 0.75 | NR3C2 (0.54) | NR3C2MAPK14 | |
| SCHEMBL501285 | 0.74 | L3MBTL1 (0.52) | NR3C2MAPK14 | |
| SCHEMBL7671508 | 0.74 | L3MBTL1 (0.52) | NR3C2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | NR3C2 1034/4885MAPK14 4/4885MAPK13 1/4885 |
| US-20210214378-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | NR3C2 1034/4885MAPK14 4/4885MAPK13 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.